Montserrat Alemany
YOU?
Author Swipe
View article: Harnessing transcriptional regulation of alternative end-joining to predict cancer treatment
Harnessing transcriptional regulation of alternative end-joining to predict cancer treatment Open
Alternative end-joining (alt-EJ) is an error-prone DNA repair pathway that cancer cells deficient in homologous recombination rely on, making them vulnerable to synthetic lethality via inhibition of poly(ADP-ribose) polymerase (PARP). Targ…
View article: Reaching the point-of-no-return: The cornerstone of glioblastoma treatment?
Reaching the point-of-no-return: The cornerstone of glioblastoma treatment? Open
The activation of cellular death programs does not necessarily predetermine an inevitable outcome. Identifying the precise moment when a cell irreversibly transitions from life to death presents a significant challenge in its assessment an…
View article: Normal Pressure Hydrocephalus Following Cranial Radiation: Identification of Shunting Responders
Normal Pressure Hydrocephalus Following Cranial Radiation: Identification of Shunting Responders Open
Background: We examined cognitive, brain MRI, and lumbar infusion test (LIT) features to identify predictors of response to ventriculoperitoneal shunting (VPS) in long-term cancer survivors with suspected normal pressure hydrocephalus (NPH…
View article: Normal pressure hydrocephalus following cranial radiation: identification of shunting responders
Normal pressure hydrocephalus following cranial radiation: identification of shunting responders Open
Purpose Normal pressure hydrocephalus (NPH) following cranial radiotherapy (RT) has a deleterious effect on patient’s daily functioning. However, there is no consensus on its management in cancer population. The aim of our study is to exam…
View article: Predictive Biomarkers of Oxaliplatin-Induced Peripheral Neurotoxicity
Predictive Biomarkers of Oxaliplatin-Induced Peripheral Neurotoxicity Open
Oxaliplatin (OXA) is a platinum compound primarily used in the treatment of gastrointestinal cancer. OXA-induced peripheral neurotoxicity (OXAIPN) is the major non-hematological dose-limiting toxicity of OXA-based chemotherapy and includes…
View article: P10.04 Incidence and characteristics of neurological adverse events secondary to immunotherapy with checkpoint inhibitors
P10.04 Incidence and characteristics of neurological adverse events secondary to immunotherapy with checkpoint inhibitors Open
BACKGROUND To explore the incidence and clinical phenotype of serious neurological adverse events (NAEs) in cancer patients who received immunotherapy with checkpoint inhibitors (ICIs) at two institutions. MATERIAL AND METHODS We reviewed …